{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:16:24Z","timestamp":1788261384118,"version":"build-2803163510"},"reference-count":53,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.1080\/17446651.2026.2713482","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:36:02Z","timestamp":1785497762000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Crinecerfont: emerging role in the management of congenital adrenal hyperplasia"],"prefix":"10.1080","volume":"21","author":[{"given":"Olga","family":"Fedorova","sequence":"first","affiliation":[{"name":"Mediclinic Parkview Hospital, Mediclinic Middle East","place":["Dubai, UAE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-6987","authenticated-orcid":false,"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Karolinska Institutet","place":["Stockholm, Sweden"]},{"name":"Karolinska University Hospital","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70007-X"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab016"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526401"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0712"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0731-6"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf018"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1528"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnae026"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001583"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad134"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00493"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab712"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818821294"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2022-0009"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00217"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1693063"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000522260"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02216-7"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab051"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae759"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13813"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5315059"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0794"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100627"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1719376"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.172"},{"key":"e_1_3_3_31_1","unstructured":"Crinetics Pharmaceuticals Inc. A double-blind randomized placebo-controlled single and multiple ascending dose study to evaluate the safety pharmacokinetics and pharmacodynamics of CRN04894 in healthy volunteers [Internet]. ClinicalTrials.Gov identifier: NCT06048887. Bethesda (MD): National Library of Medicine (US); 2023 Sep 21 [cited 2025 Oct 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06048887"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.249"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.408"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.320"},{"key":"e_1_3_3_35_1","unstructured":"Nasdaq. Crinetics pharmaceuticals reports progress on paltusotine NDA and atumelnant Phase 3 study amid strong financial position [Internet]. Nasdaq. 2025 May 8 [cited 2025 Aug 25]. Available from: https:\/\/www.nasdaq.com\/articles\/crinetics-pharmaceuticals-reports-progress-paltusotine-nda-and-atumelnant-phase-3-study"},{"key":"e_1_3_3_36_1","volume-title":"Presented at: Endocrine Society\u2019s Annual Meeting (ENDO 2025)","author":"Malet Sanz L","year":"2025","unstructured":"Malet Sanz L, Soave M, Sengmany K, et al. Optimizing binding kinetics to develop insurmountable MC2 receptor antagonists for the treatment of congenital adrenal hyperplasia. In: Presented at: Endocrine Society\u2019s Annual Meeting (ENDO 2025); San Francisco, (CA), USA; 2025 Jul 12\u201315. Abstract SUN-432."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.285"},{"key":"e_1_3_3_38_1","unstructured":"Lundbeck A\/S H. A multi-site open-label sequential-group multiple-dose trial to investigate the safety tolerability pharmacokinetics and pharmacodynamic effects of Lu AG13909 in participants with congenital adrenal hyperplasia [Internet]. ClinicalTrials.Gov identifier: NCT05669950. Bethesda (MD): National Library of Medicine (US); 2023 Jan 3 [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05669950"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.226"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab438"},{"key":"e_1_3_3_41_1","unstructured":"Spruce Biosciences. Spruce Biosciences announces topline results from CAHmelia-204 adult trial [Internet]. South San Francisco (CA): Spruce Biosciences; 2024 Dec 10 [cited 2025 Feb 24].Available from: https:\/\/investors.sprucebio.com\/news-releases\/news-release-details\/spruce-biosciences-announces-topline-results-cahmelia-204-adult"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01089-w"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1647028"},{"key":"e_1_3_3_44_1","unstructured":"PubChem [Internet]. PubChem compound summary for CID 5282340. Bethesda (MD): National Library of Medicine (US) National Center for Biotechnology Information; 2004 [cited 2025 Oct 15]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Crinecerfont"},{"key":"e_1_3_3_45_1","unstructured":"U.S. Food and Drug Administration. Crinecerfont: other review \/ other documents [Internet]. NDA 218808\/218820. Silver Spring (MD): U.S. Food and Drug Administration; 2024 [cited 2025 Nov 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218808Orig1s000 218820Orig1s000OtherR.pdf"},{"key":"e_1_3_3_46_1","unstructured":"National Library of Medicine (US). U.S. Food & Drug Administration. Prescribing Information: CRENESSITY (crinecerfont) capsules and oral solution. 2024. Available from cited 2025 Oct 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218808s000 218820s000lbl.pdf"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404656"},{"key":"e_1_3_3_48_1","unstructured":"U.S. Food and Drug Administration. Crinecerfont: integrated review [Internet]. NDA 218808\/218820. Silver Spring (MD): Center for Drug Evaluation and Research (CDER); 2024 [cited 2025 Nov 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218808Orig1s000 218820Orig1s000IntegratedR.pdf"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab749"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad270"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404655"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2024-0440"},{"key":"e_1_3_3_53_1","unstructured":"Neurocrine Biosciences. Global safety and efficacy registration study of crinecerfont for congenital adrenal hyperplasia [Internet]. ClinicalTrials.Gov identifier: nCT04490915. 2020 [cited 2025 Oct 28]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04490915"},{"key":"e_1_3_3_54_1","unstructured":"Crinecerfont. LiverTox: clinical and research Information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [cited 2025 Feb 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK612555\/"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.01.010"}],"container-title":["Expert Review of Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17446651.2026.2713482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17446651.2026.2713482","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17446651.2026.2713482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:32:46Z","timestamp":1788258766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17446651.2026.2713482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,3]]}},"alternative-id":["10.1080\/17446651.2026.2713482"],"URL":"https:\/\/doi.org\/10.1080\/17446651.2026.2713482","relation":{},"ISSN":["1744-6651","1744-8417"],"issn-type":[{"value":"1744-6651","type":"print"},{"value":"1744-8417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iere20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iere20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}